In 2023, Kane Biotech has been featured in several news media articles, including BNN Bloomberg and Benzinga, as well as a podcast with proactiveinvestors.com. Kane is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. With a
The largest organ in a human body is the skin, and each person’s skin is 100% unique. That is why it is so important that your scalp products are perfectly tailored to your unique skin challenges. DermaKB™ products are developed by Kane Biotech, who is leading the
It is fascinating to think of how the earliest humans learned how to treat wounds, as the earliest historical evidence dates back as far back as 2200 BC with a clay tablet that bears three images of a wound being washed, a plaster of mud
As 2022 draws to a close, Kane Biotech reflects upon its achievements in the last year. Kane refers to itself as THE Biofilm Company, with over 80 patents and patents pending. Kane focused its efforts in 2022 on further developing its wound care product pipeline
As researchers continue to study the impacts of biofilms on wounds, individuals living with chronic wounds often experience a negative impact on their overall physical and mental health, especially for those whose wounds continue for months or even years. Chronic wound patients commonly report concerns
Kane Biotech experienced significant achievements in October 2022, for both their coactiv+™ and their DispersinB® technologies. For over 20 years, Kane has been developing new technologies and innovations, leading to 80 patents and patents pending in biotechnology focusing primarily on biofilm. Kane Biotech Announces 510(k)
Antimicrobial resistance (AR) occurs when bacteria are exposed to levels of antibiotics that fail to kill the bacteria. For example, when an antibiotic that was able to treat an infection previously is no longer able to effectively kill bacteria, and results in an ongoing or
The National Institute of Health reports that 80% of all known human infections are associated with biofilms. Biofilms are a serious and urgent clinical and financial burden to health care systems and patients, costing industry, cities, and hospitals over $500 billion each year. What are
If you have never heard of biofilms before, you are not alone. Biofilms may be an uncommon word, but they impact our lives and health in many ways – including keeping us sick. A simple way to describe a biofilm is it being a glue-like
For those living with diabetes, Diabetic foot ulcers (DFUs) can be a severe condition with tremendous economic and physical impacts on patients and their caregivers. However, one of the main reasons that DFUs are difficult to heal is likely related to the existence of biofilms.
